Good evening :)
$
₹
O

Obsidian Therapeutics, Inc. Common Stock

OBX

NASDAQ
O

Obsidian Therapeutics, Inc. Common Stock

OBX

NASDAQ
$13.841.00% (-0.14)
$
₹
$13.841.00% (-0.14)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $863.6M the stock is ranked 2834

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.63
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 5 analysts reports

Buy
5 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+178.97%

Earnings Growth

-100.53%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

2026
Current$13.98Baseline
Analyst Target - 1 year
Target$39+178.97%

All values in $

20232024202520262027$20.16$27.74$35.32Target+178.97%
2026
Current$13.98Baseline
Analyst Target - 1 year
Target$39+178.97%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$345.33Baseline
Forecast for Dec 2026
High$-1-100.29%
Average$-1.82-100.53%
Low$-2.62-100.76%

All values in $

20222023202420252026N/AN/AN/A345.33Low-100.76%Average-100.53%High-100.29%
2025
Current$345.33Baseline
Forecast for Dec 2026
High$-1-100.29%
Average$-1.82-100.53%
Low$-2.62-100.76%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-24.9
-19.6
Q1 2023
Q2 2023
Q1 2025
Q1 2026
Revenue
Net Income
Financial YearQ4 2022Q1 2023Q2 2023Q1 2025Q1 2026
Total Revenue---00
Net Income----24.98-19.63
Net Profit Margin-----
See CostsAll values in $ Million

Peers

Price Comparison

Compare OBX with any stocks or ETF

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Frequently asked questions

  1. Obsidian Therapeutics, Inc. Common Stock (OBX) share price today is $13.84 as of October 26, 2026 at 11:11 PM IST. The stock touched a day high of $14.08 and a day low of $13.19.

  2. Obsidian Therapeutics, Inc. Common Stock stock trades on NASDAQ under the ticker symbol OBX.

  3. Obsidian Therapeutics, Inc. Common Stock's market capitalization is $863.58M as of October 26, 2026 at 11:11 PM IST.

  4. Obsidian Therapeutics, Inc. Common Stock's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Obsidian Therapeutics, Inc. Common Stock's price-to-book (P/B) ratio is 0 as of October 26, 2026.

  6. Yes, You can buy Obsidian Therapeutics, Inc. Common Stock shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Obsidian Therapeutics, Inc. Common Stock shares in three steps: 1. Search Obsidian Therapeutics, Inc. Common Stock on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Obsidian Therapeutics, Inc. Common Stock trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Obsidian Therapeutics, Inc. Common Stock (OBX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.7225 shares at the current price of $13.84.

Loading...